Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227

Peter M. Anderson1*, Vivek Subbiah2,3 and Matteo M. Trucco1

1Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, Cleveland Clinic Children’s Hospital, Pediatric Institute, Cleveland Clinic, Cleveland, OH, United States, 2Investigational Cancer Therapeutics, Cancer Medicine, Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Osteosarcoma is a high-grade sarcoma characterized by osteoid formation, nearly universal expression of IGF1R and with a subset expressing HER-2. These qualities provide opportunities for the use of the alpha particle-emitting isotopes to provide targeted radiation therapy via alpha particles precisely to bone-forming tumors in addition to IGF1R or Her-2 expressing metastases. This review will detail experience using the alpha emitter radium-223 (223Ra, tradename Xofigo), that targets bone formation, in osteosarcoma, specifically related to patient selection, use of gemcitabine for radiosensitization, and using denosumab to increasing the osteoblastic phenotype of these cancers. A case of an inoperable left upper lobe vertebral-paraspinal-mediastinal osteoblastic lesion treated successfully with 223Ra combined with gemcitabine is described. Because not all areas of osteosarcoma lesions are osteoblastic, but nearly all osteosarcoma cells overexpress IGF1R, and some subsets expressing Her-2, the anti-IGF1R antibody FPI-1434 linked to actinium-225 (225Ac) or the Her-2 antibody linked to thorium-227 (227Th) may become other means to provide targeted alpha particle therapy against osteosarcoma (NCT03746431 and NCT04147819).

KEYWORDS
osteosarcoma, osteoblastic metastases, bone metastases, lung metastases, radiosensitization, denosumab, IGF1R antibody FPI-1434-225Ac

Biologic characteristics of osteosarcoma, a bone forming cancer

Pathologic diagnosis of osteosarcoma requires the demonstration of bone formation in the form of osteoid production (1). Despite accurate pathologic diagnosis, genomic instability has resulted in osteosarcomas having heterogeneous molecular signatures, with a relative paucity of actionable molecular targets. Many osteosarcoma tumors and metastases harbor p53 mutations or other mechanisms (e.g., MDM2 amplification) that
interfere with apoptosis after damage from standard chemotherapy, newer agents such as tyrosine kinase inhibitors (TKI) of vascular endothelial growth factor (VEGF) (2, 3), and/or radiation therapy (4, 5).

Although osteosarcoma has long been considered relatively radio-resistant (6), this assessment was in the pre-chemotherapy era; radiotherapy has been shown to be more effective against osteosarcoma when given in combination with chemotherapy (5, 7–10) or using proton radiotherapy (11). Another approach that is more biologically effective for bone metastases than conventional low dose fractionated radiation to enhance radiation effectiveness is stereotactic body radiotherapy (SBRT) which delivers precise high dose fractions (12–17). The high Linear Energy Transfer (LET) of alpha particles emitted by $^{223}$Ra, $^{223}$Ac, or $^{227}$Th causes hard to repair double strand breaks, providing another way to potentially overcome the intrinsic biologic resistance of osteosarcoma to radiotherapy (18–20).

**Current therapy of osteosarcoma**

The importance of local control measures, especially surgery was shown in a series by Jaffe (21). Current osteosarcoma protocols use variations of the 3-drug (Methotrexate Adriamycin, Platinum, MAP) or 5-drug (MAP + Ifosfamide/etoposide, MAPIE) chemotherapy similar to that reported by the Euramos-1 study (22, 23). The addition of Mifamurtide may also improve outcomes (24–27). Metastatic disease, age > 18 (28) and poor response to neoadjuvant chemotherapy are associated with worse prognosis that to date we have not been able to effectively overcome (29, 30).

Ifosfamide is clearly an active drug in osteosarcoma as shown by its effectiveness against bone metastases and responses in patients not responding to MAP (31). Ifosfamide/mesna can be given with reduced toxicity and improved quality of life when given as an outpatient (32–37). If surgery is not possible or would have an unacceptable effect on the quality of life after response to ifosfamide/mesna, then use of not only radiotherapy with radio-sensitizers (10), but also alpha emitting radiopharmaceuticals such as $^{223}$Ra can provide options for local and systemic control (12, 17).

**Alpha emitter radium-223 for osteosarcoma**

**Osteoblastic phenotype is necessary for bone-seeking radiopharmaceutical targeting against osteosarcoma**

An osteoblastic phenotype is often suspected when calcified osteosarcoma metastases are seen on scans. However, active bone formation for the metastases >1 cm should be demonstrated using $^{99m}$Tc-MDP bone scan or $^{18}$FNa bone PET-CT before contemplating use of $^{223}$Ra in osteosarcoma (12, 17). Better images are obtained when planar images are combined with CT (SPECT-CT). $^{18}$FNa bone PET-CT has increased sensitivity toward osteoblastic metastases and, because a standard uptake value can be obtained on individual metastases, $^{18}$FNa bone PET-CT also provides a semi-quantitative assessment of disease burden that can be followed to measure the treatment response (38–46). Radiation is excellent if delivered precisely to tumors avoiding normal tissue. Thus, if there is avid $^{99m}$Tc-MDP and/or $^{18}$FNa uptake in osteosarcoma metastases or a local recurrence, then the patient is excellent candidate for the use of $^{223}$Ra to deliver alpha particle radiation to osteoblastic osteosarcoma tumors and minimal radiation to the surrounding normal tissues, be it adjacent lung, spine, or limb salvage hardware from prior surgeries. If little or no bone formation is seen on these imaging modalities, then the patient is not a good candidate for $^{223}$Ra.

We have given $^{223}$Ra in osteosarcoma using the standard dose and monthly infusion schedule of 1.49 microCi/kg intravenously monthly (12) and at 50, 75, and 100 kBq/kg in a dose escalation study (48). From the perspective of the patient, getting $^{223}$Ra is relatively simple: there is a discussion of the minimal radiation safety requirements (wash hands, flush toilet twice), and, because one unbound $^{223}$Ra comes out in the stool, and in our Nuclear Medicine Departments getting $^{223}$Ra is similar to getting a bone scan injection and takes approximately 10 min. Our current practice is to use the standard $^{223}$Ra dose on a Wednesday or Thursday to allow gemcitabine to be given as a radio-sensitizer the following day. We also use $^{223}$Ra in combination with other agents such as denosumab and local control measures in an attempt to both improve the efficacy of $^{223}$Ra and also to treat areas of metastases that do not have $^{223}$Ra deposition as illustrated in Figure 1.

**Improving therapeutic index of radium-223 in osteosarcoma**

**Denosumab**

Denosumab is a fully humanized anti-RANKL antibody that improves bone density. It is used to treat osteoporosis, reduce skeletal complications of bone metastases, and treat giant cell tumor of bone (49–53). We have made the observation that some osteosarcomas increase the amount of bone formation after denosumab. Thus, monthly denosumab injections during $^{223}$Ra therapy can increase the amount of $^{223}$Ra deposited in osteoblastic metastases in osteosarcoma (12).

**Gemcitabine**

Gemcitabine is an excellent radio-sensitizer (10, 54–59). The toxicity of gemcitabine is dependent on not only schedule...
FIGURE 1
Algorithm of treatment of metastatic, recurrent osteosarcoma with systemic agents, local control measures, and with alpha-emitters $^{223}$Ra or Anti-IGF1R-Actinium-225. Note if unresectable, referral to a center with expertise in administration of alpha emitters in combination with radiotherapy will be needed.

Anderson et al. 10.3389/fmed.2022.1030094

and dose, but also infusion duration. Shorter infusions (30 min) are associated with less hematologic toxicity than 90 min infusions. Gemcitabine is given daily $5 \times$ had unacceptable mucosal toxicity. Weekly or day 1 and 8 of 3-week cycles are better tolerated. Since gemcitabine must be taken up and phosphorylated to act on the cancer cell, longer infusion times are associated with more hematologic toxicity (60, 61). Giving gemcitabine 600 mg/m$^2$ intravenously (iv) once over 30 min 1 day after $^{223}$Ra is deposited in osteoblastic tumors is a convenient monthly strategy that allows gemcitabine to increase effects within osteoblastic metastases with minimal hematologic toxicity.

Case report
The following case (Figure 2) illustrates the successful use of $^{223}$Ra and gemcitabine (62). A 27-year-old patient presented with a large osteosarcoma tumor involving T2-4 extending into both the spinal canal and the left upper lobe. Because of giant cell features, he was initially given denosumab, but when molecular testing revealed FGFR mutation and pathology was reviewed, the diagnosis of osteosarcoma was made. He received 2 cycles of MAP chemotherapy and then because of minimal response was switched to ifosfamide + etoposide. Because the tumor was deemed unresectable, 50.4 Gy over 28 fractions with concurrent ifosfamide + etoposide was given during cycles 5 and 6. He received 2 more cycles of ifosfamide + etoposide then had radiographic progression and clinical worsening (weakness of both lower extremities, some tingling, and need to use a cane). Cardiotoracic, orthopedic, and spine surgeons reviewed his case at the sarcoma conference at the Cleveland Clinic and also deemed the tumor to be unresectable because of the combination of vertebral, spinal canal, and mediastinal involvement. Bone scan with Spect-CT showed avid $^{99m}$Tc-MDP uptake and he was given 6 monthly cycles of Denosumab, $^{223}$Ra, followed by gemcitabine. Cytopenias were modest, no transfusions were needed. The patient experienced a clinical response as characterized by increased strength in his legs, no longer requiring a cane to ambulate and resolution of paresthesia. Uptake of $^{18}$FDG as well and $^{99m}$Tc-MDP was decreased on repeat imaging. After the response to $^{223}$Ra monthly $6 \times$, he was given oral cyclophosphamide for 6 months (Figure 2). He is now over 9 months off therapy without evidence of recurrence. His activity level has increased and he is able to skateboard (even able to do tricks such as a “trellip,” insert top on Figure 2; Supplementary Video 1), rock climbs often, and has gone skydiving six times.

Other chemotherapy agents worth determining suitability in combination with radium-223 in osteosarcoma
Local and systemic therapy is often needed before the logistics of evaluating osteoblastic phenotype and obtaining $^{223}$Ra for osteosarcoma treatment can be solved. Some active agents in the relapsed metastatic osteosarcoma setting are illustrated in Figure 1 (ifosfamide, TKI, and doxorubicin liposomes). Since many patients have had MAP initially without
ifosfamide, ifosfamide with or without etoposide is often the 2nd line therapy of choice (31–34). When ifosfamide is given with mesna as a continuous infusion, thrombocytopenia, encephalopathy, and renal toxicity are seen less often (33–37, 63). We have also demonstrated that outpatient continuous infusion of ifosfamide + mesna was associated with fewer transfusions and episodes of fever and neutropenia (63). If continuous infusion of ifosfamide + mesna is to be used with $^{223}$Ra, we would recommend starting 1 day after $^{223}$Ra administration using a dose of 1 gm/m$^2$/d × 1 week. Administration of PEG–GCSF after completion of the ifosfamide infusion is also recommended. This regimen can be repeated every 4 weeks to allow for the cytotoxic effects when the bone-seeking radiopharmaceutical is most active in bone-forming lesions and to allow for hematologic recovery as $^{223}$Ra decays.

Tyrosine kinase inhibitors including regorafenib (2, 64) and cabozantinib (3) have efficacy against osteosarcoma. Although a dose adjustment of TKI is sometimes needed to limit skin or GI toxicity, we have found the use of glutamine-disaccharide (Healios) can be helpful in ameliorating GI side effects and helping in eating and nutrition while on these agents (35).

Liposomal doxorubicin (tradenames Doxil or Caelyx) has very low heart toxicity (65, 66). This preparation can be given monthly and has modest hematologic toxicity and is not associated with alopecia when given at 40 mg/m$^2$. Thus liposomal doxorubicin has high patient acceptance among relapsed osteosarcoma patients. Cold packs on hands, feet, and the use of glutamine + disaccharide (Healios) can be used to limit hand/foot erythroderma and mucositis/esophagitis, respectively (35). Liposomal doxorubicin is probably most suitable in relapsed osteosarcoma patients who had an initial excellent response to MAP chemotherapy. There is also a clinical trial using liposomal doxorubicin in combination with disulfiram to try to target slowly repopulating cancer stem cells high in aldehyde dehydrogenase (67, 68) (NCT05210374 M. Trucco, PI).

Use of local control measures including stereotactic body radiotherapy before or in combination with radium-223

As illustrated in Figure 1, surgery, cryoablation, and/or radiation can provide local control of osteosarcoma metastases. Location and number of metastases ("oligometastatic" is <10) may determine whether to do surgery, cryoablation, or to definitively treat with radiation (e.g., 3 Gy × 20 fractions RT or SBRT 8 Gy × 5 fractions = 40 Gy) or whether palliative radiation (e.g., 3 Gy × 10 fractions) is most appropriate. Reasons to use local control include treatment or prevention of pain as well as reduction of tumor burden, particularly where tumor growth may cause complications (e.g., spine or sacral metastases, and hilar or mediastinal metastases. Unfortunately, for the most common pattern of end-stage metastases (numerous lung
TABLE 1 Alpha emitters for osteosarcoma.

| Radiopharmaceutical  | $^{223}$RaCl2 | $^{225}$Ac-anti-IGF1R | $^{227}$Th-Anti-Her2 |
|----------------------|---------------|-----------------------|---------------------|
| Half-life of radio-metal | 11.4 days    | 10 days               | 18.7 days           |
| Alpha Particles emitted | 4            | 4                     | 5                   |
| Blood clearance       | Rapid (<1% at 24 h) | Antibody clearance | Antibody clearance |
| Radon daughter half-life | 4 s         | no radon daughter     | 4 s                 |
| Penetration of radioisotope | 0.1 mm     | 0.1 mm                | 0.1 mm              |
| Imaging with gamma camera | Possible | Not done              | Possible            |
| Decays to stable isotope | 207-Pb     | 209-Bi                | 207-Pb              |

IGF-1R expression in osteosarcoma: An opportunity for anti-IGF-1R antibody-actinium-225 alpha particle therapy

Sarcomas, particularly Ewing sarcoma and osteosarcoma have overexpression of IGF1R (69). Although cold antibody was only modestly effective in Ewing sarcoma and not in osteosarcoma (69), chelation of the alpha emitter $^{225}$Ac can arm the anti-IGF1R antibody to become a potent alpha emitter (70, 71). Table 1 compares $^{223}$Ra, which targets areas of bone turnover, with anti-IGF1R-Actinium-225. Currently, the clinical trial NCT03746431 is open at MD Anderson Cancer Center, City of Hope, Memorial Sloan Kettering, University of Minnesota, Dana Farber Cancer Institute, University of Pennsylvania, Juravinski/Hamilton Health, CHU-Montreal, Princess Margaret (Toronto), and CHU Quebec. We expect patients <18 years old to be able to be enrolled when the recommended phase 2 dose is achieved. Thus, the anti-IGF1R-Actinium-225 strategy may be another way to treat osteosarcoma metastases that are not osteoblastic and with alpha-particle radiation that effectively acts at short distances in a powerful manner. Nevertheless, the expression of IGF-1R in normal tissue and/or non-specific binding of antibodies may limit the effectiveness of this approach.

Her-2 expression in osteosarcoma: An opportunity for targeted thorium conjugates

Her-2 is expressed in a subset of osteosarcomas. Earlier attempts to target this Her2 expression using trastuzumab were unsuccessful. However, clinical trials using Her2-targeted CAR T-cells suggest that Her2-targeted therapy could be active in osteosarcoma (72). Moreover, better-designed novel antibody drug conjugates like Trastuzumab-Deruxtecan (T-DXd) is showing activity in low Her-2 expressing breast cancers, are also being explored in osteosarcoma. HER2-thorium-227 targeted conjugate (TTC) has recently entered clinical trials in Europe and the USA. "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes, and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein" (NCT04147819) is a combination of the alpha-emitting radionuclide thorium-227, an antibody targeting HER2, and a chelator molecule that strongly attaches the thorium-227 to the antibody. This technology harnesses the antibody's ability to target HER2 by using it to transport the alpha particle emitting thorium-227 to the tumor. Both radium-223 and thorium-227 decay produce alpha particle radiation (Table 1) that causes highly lethal double strand DNA damage in tumor cells, but also useful emission for gamma scintigraphy (73). Although the first in human trial is open for breast and gastric only, the expansion part of the study will include patients with a range of tumor indications with HER2 expression which occurs on osteosarcoma. Only in the context of a clinical trial will it be possible to determine whether benefits for the binding to HER-2 on osteosarcoma outweigh potential toxicity from expression on normal cells and/or non-specific binding of the alpha emitter.

Summary and conclusion

Alpha emitters have some potent biological advantages that may eventually prove useful for the treatment of osteosarcoma. However, the rarity of this sarcoma and specific situations to test efficacy in randomized clinical trials will be very difficult. Perhaps the use of patients as their own controls with benefit as improved quality of life and/or clinical course better than expected—especially compared to historical controls (74) is possibly the best we can do currently.

Author contributions

PA: writing of the manuscript and experience with $^{223}$Ra combination therapy. VS: editing of manuscript and experience with $^{223}$Ra, anti-IGF1R-Ac225 antibody, and Her-2 TTC. MT: editing of manuscript and current treatment of relapsed osteosarcoma including doxorubicin liposomes with or without disulfiram. All authors contributed to the article and approved the submitted version.
Funding

This work was funded by the Cleveland Clinic Sarcoma program. VS was an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center. VS acknowledged the support of the Jacquelyn A. Brady Fund. VS was supported by the US National Institutes of Health (NIH) (Grant nos. R01CA242845 and R01CA273168), the MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (Grant no. RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Grant no. 1U01 CA180964), the NCATS (Center for Clinical and Translational Sciences) (Grant no. UL1 TR000371), and the MD Anderson Cancer Center Support (Grant no. P30 CA016672).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

The efforts of physicians and physiicians in the Departments of Nuclear Medicine at MD Anderson and Cleveland Clinic area acknowledged. The efforts of the C level and Clinic Pediatric Hematology/Oncology infusion nurses and care coordination by Shauna Sartoski, RN for Pediatric Hematology/Oncology infusion nurses and care coordination by Shauna Sartoski, RN for

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.1030094/full#supplementary-material

SUPPLEMENTARY VIDEO 1
Excellent return of lower extremity function after 223-Ra treatment of thoracic paraspinal osteosarcoma as demonstrated by skateboarding.

References

1. Rivera-Valentin RK, Zha L, Hughes DP. Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy. Paediatr Drugs. (2015) 17:257–71. doi: 10.1007/s40272-015-0134-4
2. Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. (2019) 20:120–33. doi: 10.1016/S1470-2045(18)30742-3
3. Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. (2020) 21:446–55. doi: 10.1016/S1470-2045(19)30825-3
4. Prudowsky ZD, Yustein JT. Recent insights into therapy resistance in osteosarcoma. Cancers. (2020) 13:83. doi: 10.3390/cancers13010083
5. Hernberg MM, Kvioja AH, Böhling TO, Janes RJ, Wiklund TA. Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma. Med Oncol. (2011) 28:1475–80. doi: 10.1007/s12032-010-9592-2
6. Dahlin DC. Prognostic factors in osteosarcoma. Int J Radiat Oncol Biol Phys. (1980) 6:1755. doi: 10.1016/0360-3016(80)90266-7
7. Machak GN, Tkachev SI, Solovyev YN, Izyuvkov PA, Ivanov SM, Kochergina NV, et al. Nesaduvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc. (2003) 78:147–55. doi: 10.4065/78.2.147
8. Anderson PM. Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. Mayo Clin Proc. (2003) 78:145–6. doi: 10.4065/78.2.145
9. Mahajan A, Woo SY, Kornguth DG, Hughes D, Huh W, Chang EL, et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer. (2008) 50:976–82. doi: 10.1002/pbc.21451
10. Anderson P, Aguilera D, Pearson M, Woo S. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control. (2008) 15:38–46. doi: 10.1177/107327480801500105
11. Patel S, DeLaaney TF. Advanced-technology radiation therapy for bone sarcomas. Cancer Control. (2008) 15:21–37. doi: 10.1177/107327480801500104
12. Anderson PM, Scott J, Parsai S, Zahler S, Worley S, Shirkhanth S, et al. 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. ESMO Open. (2020) 5:e000635. doi: 10.1136/esmoopen-2019-000635
13. Baumann BC, Bernstein KA, DeLaaney TF, Simone CB II, Kolker JD, Choy E, et al. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. J Surg Oncol. (2020) 122:877–83. doi: 10.1002/jso.26078
14. Baumann BC, Nagda SN, Kolker JD, Levin WP, Weber KL, Berman AT, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection. J Surg Oncol. (2016) 114:65–9. doi: 10.1002/jso.24268
15. Park C, Papies L, Zhang S, Story M, Zimmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. (2008) 70:847–52. doi: 10.1016/j.ijrobp.2007.10.059
16. Anderson PM, Subhiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. (2014) 804:291–304. doi: 10.1007/978-3-319-04843-7_16
metastatic osteosarcoma: a pediatric oncology group trial. et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed Blood Cancer. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Herzog C, et al. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Janeway KA, Barkauskas DA, Schwartz CL, Ebb DH, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Bielack SS, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, et al. Grade 22. Bielack SS, Carrasco H, Raymond K, Ayala A, Effekhari F. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. (2015) 33:2279–87. Marina NM, Smeland S, Bielack SS, Bernstein ML, Jovic G, Kraalo MD, et al. Comparison of MAP1E versus MAP in patients with a poor response to preoperative radiotherapy: a report from the Children's Oncology Group. Cancer. (2009) 115:5339–48. Anderson P. Continuously improving ifosfamide/mesna: a winning combination. Pediatr Blood Cancer. (2002) 40:238–44. Meazza C, Bisogno G, Casanova M, Zanetti I, Carli M, Ferrari A. Full-dose ifosfamide can be safely administered to outpatients. Pediatr Blood Cancer. (2010) 58:397–58. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in pediatric osteosarcoma: a report from the Children's Oncology Group. Cancer. (2003) 19:2087–97. Anderson et al. 10.3389/fmed.2022.1030094
57. Lawrence TS, Chang EY, Hahn TM, Shewach DS. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). Clin Cancer Res. (1997) 3:777–82.
58. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Radiosensitization by gemcitabine. Oncology. (1999) 13(10 Suppl 3):55–60.
59. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol. (1997) 24(2 Suppl 7):57–24.
60. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. (1997) 15:351–41. doi: 10.1023/A:1005981317532.
61. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenn R. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. (2003) 21:3402–8. doi: 10.1200/JCO.2003.09.140.
62. Anderson PM. Radium Knocks out Tumor cells in Case of Unresectable Paraspinal osteosarcoma. New York, NY: Consult QD (2022).
63. Plutt AA, Stanton MP, Zembillas AS, Pierson CE, Zahler S, Anderson PM, et al. Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population. J Pediatric Hematol Oncol. (2021) [Epub ahead of print]. doi: 10.1097/MPH.0000000000002361.
64. Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C, Bawa O, Opolon P, Vievard A, et al. Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models. PLoS One. (2015) 10:e0142812. doi: 10.1371/journal.pone.0142612.
65. Blank N, Laskow I, Kessous R, Kogan L, Lau S, Sebag IA, et al. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol. (2017) 80:737–43. doi: 10.1007/s00280-017-3412-8.
66. Skubitz KM, Blaes AH, Konety SH, Francis GS. Cardiac safety profile of patients receiving high cumulative doses of pegylated liposomal doxorubicin. use of left ventricular ejection fraction is of proven value. Cancer Chemother Pharmacol. (2017) 80:787–98. doi: 10.1007/s00280-017-3420-8.
67. Tomita H, Tanaka K, Tanaka T, Harada A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. (2016) 7:11018–32. doi: 10.18632/oncotarget.9230.
68. Kang JH, Lee SH, Hong D, Lee JS, Ahn HS, Ahn JH, et al. Aldehyde dehydrogenase is used by cancer cells for energy metabolism. Exp Mol Med. (2016) 48:e272. doi: 10.1038/emm.2016.103.
69. Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. (2016) 63:1761–70. doi: 10.1002/pbc.26087.
70. Thiele NA, Wilson JJ. Actinium-225 for targeted alpha therapy: coordination chemistry and current chelation approaches. Cancer Biother Radiopharm. (2018) 33:336–48. doi: 10.1089/cbr.2018.2494.
71. Muller C, van der Meulen NP, Beneslova M, Schibbi R. Therapeutic Radiomets Beyond (177)Lu and (90)Y: production and application of promising alpha-particle, beta(-)-particle, and auger electron emitters. J Nucl Med. (2017) 58(Suppl 2):91S–6S. doi: 10.2967/jnumed.116.186825.
72. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. (2015) 33:1688–96. doi: 10.1200/JCO.2014.58.0225.
73. Murray I, Rojas B, Gear J, Callister R, Cleton A, Flux GD. Quantitative dual-isotope planar imaging of thorium-227 and Radium-223 using defined energy windows. Cancer Biother Radiopharm. (2020) 35:530–9. doi: 10.1089/cbr.2019.3554.
74. Lagmay JP, Kraulo MD, Dang H, Kim A, Hawkins DS, Beatty O III, et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II Trials through children's cancer group, pediatric oncology group, and children's oncology group: learning from the past to move forward. J Clin Oncol. (2016) 34:3031–8. doi: 10.1200/JCO.2015.65.5381.